UNSPSC 51332524: Moperone hydrochloride

This classification denotes an anxiolytic C22H26FNO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z2633815T, chemically known as butyrophenone, 4'-fluoro-4-(4-hydroxy-4-p-tolylpiperidino)-, hydrochloride, but more generally known as moperone hydrochloride, which bears US NIH Compound Identifier 19747. European Medicines Agency schedules Moperone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03326MIG.

Most nations, for tariff and trade purposes, schedule moperone hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, MOPERONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC(CC1)C2(CCN(CC2)CCCC(=O)C3CCC(CC3)F)O.CL.

UNSPSC 51332524 Moperone hydrochloride is a Commodity code that in practice captures state and local procurement of pharmaceutical products, naloxone, drug deactivation systems, and generic multi-source pharmaceuticals for public health and community care programs. The recent opportunities show state health agencies, county health departments, and multistate purchasing consortia soliciting finished pharmaceutical products, over-the-counter medications, and specialized health-intervention supplies to stock community health facilities, support pharmacy benefit programs, and equip first-responder and emergency-services functions. Issuing bodies include county health departments (Seminole County, Florida), state HHS commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). These solicitations target manufacturers and authorized pharmaceutical distributors capable of meeting cGMP and FDA compliance, maintaining supply-chain security certifications, and fulfilling volume orders with tiered pricing and logistics support.

Geographic activity centers on Florida, Texas, and the Upper Midwest (Minnesota, Oregon). Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities for a Therapeutic Pharmacy Initiative; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026. The MMCAP solicitation emphasizes price competitiveness (75 percent weight), cGMP and DSCSA compliance, EDI capability, and pricing flexibility across flat-fee, net-price, and WAC-minus structures.